MicuRx To Present New Data At 7th World Bronchiectasis Conference

SHANGHAI, June 19, 2024 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH), a multi-asset biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced 3 new studies will be presented at the 7th World Bronchiectasis Conference, taking place from July 4 - 6, 2024 in Dundee, Scotland.

The presentations will showcase nonclinical data for MRX-5 and MRX-8. MRX-5 is an oral investigational candidate for the treatment of adults with nontuberculous mycobacteria (NTM) pulmonary diseases. MRX-5 demonstrates potent antimicrobial activity against Mycobacterium avium complex (MAC), the most common NTM pathogen, as well as Mycobacterium abscessus complex (MABC), the more difficult-to-treat NTM. MRX-5 is currently in Phase 1 clinical studies and topline results are expected in late 3Q2024.

MRX-8 is a novel compound in the polymyxin class. Nebulized MRX-8 is developed for treating chronic Pseudomonas aeruginosa lung infection in patients with bronchiectasis, including infections caused by drug resistant isolates.

Presentations pertaining to MRX-5 and MRX-8:

Title: In Vitro And In Vivo Activity Of A Novel Leucyl-Trna Synthetase Inhibitor Against Mycobacterium Abscessus

Presenting Author: Regis Vilchez, MD, PhD (MicuRx)

Title: In Vitro Activity of Novel Leucyl-tRNA Synthetase Inhibitor Against Mycobacterium Avium Complex

Presenting Author: Wen Wang, PhD (MicuRx)

Title: In Vitro And In Vivo Activity Of A Novel Antibiotic In The Polymyxin Class Against Pseudomonas Aeruginosa

Presenting Author: Wen Wang, PhD (MicuRx)

About MicuRx

MicuRx is a biopharmaceutical company focusing on novel therapeutics for infectious diseases. With global independent intellectual property and competitiveness, we are committed to the discovery, development, and commercialization of innovative drugs for unmet medical needs. Since the company was founded in 2007, MicuRx has adhered to the principle of "Better therapy through superior medicine", focusing on the increasingly serious problem of global antimicrobial resistance.

For more information, please visit our website at www.micurx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/micurx-to-present-new-data-at-7th-world-bronchiectasis-conference-302176491.html

SOURCE MicuRx Pharmaceuticals

First published on Wed, Jun 19, 2024

Enjoyed what you read? Great news – there’s a lot more to explore!

Dive into our content repository of the latest tech news, a diverse range of articles spanning introductory guides, product reviews, trends and more, along with engaging interviews, up-to-date AI blogs and hilarious tech memes!

Also explore our collection of branded insights via informative white papers, enlightening case studies, in-depth reports, educational videos and exciting events and webinars from leading global brands.

Head to the TechDogs homepage to Know Your World of technology today!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.

Tags:

MicuRx Biopharmaceutical Novel Therapeutics Bronchiectasis Conference

Join The Discussion

Protecting Print Fleets: Symphion Addresses Complacency In Printer Endpoint Protection With Two New Offerings

School Specialty LLC Announces Acquisition Of Nasco Education U.S.

Scowtt Raises $12M Series A To Transform Performance Marketing With AI-Powered Advertising Platform

Unified.To Powers 550% API Usage Growth In Six Months Amid Rising AI Adoption

Broadridge's Distributed Ledger Repo Platform Processes $368 Billion In Average Daily Trade Volumes In November